Estimating the cost-effectiveness of an intervention in a clinical trial when partial cost information is available: A Bayesian approach

Health Economics

Volumn 17, Issue 1, 2008, Pages 67-81

  Lambert, Paul C ^a   Billingham, Lucinda J ^b   Cooper, Nicola J ^a   Sutton, Alex J ^a   Abrams, Keith R ^a  

^a UNIVERSITY OF LEICESTER   (United Kingdom)

^b UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

Bayesian methods; Cost effectiveness; Lung cancer; Missing data; Net monetary benefit

Indexed keywords

ANTINEOPLASTIC AGENT;

ADULT; ADVANCED CANCER; ARTICLE; BAYES THEOREM; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; DRUG COST; FEMALE; HEALTH CARE COST; HEALTH CARE UTILIZATION; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; PALLIATIVE THERAPY; PATIENT SELECTION; PREDICTION; PRIORITY JOURNAL; STATISTICAL DISTRIBUTION; STATISTICAL MODEL; SURVIVAL TIME;

ANTINEOPLASTIC AGENTS; BAYES THEOREM; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIALS AS TOPIC; COST-BENEFIT ANALYSIS; HUMANS; LUNG NEOPLASMS; MODELS, ECONOMETRIC; PALLIATIVE CARE;

EID: 38949157166     PISSN: 10579230     EISSN: 10991050     Source Type: Journal    
DOI: 10.1002/hec.1243     Document Type: Article

References (30)

1. Best NG, Spiegelhalter DJ, Thomas A, Brayne CEG. 1996. Bayesian-analysis of realistically complex-models. Journal of the Royal Statistical Society Series A - Statistics in Society 159: 323-342.
2. Billingham LJ, Abrams KR. 2002. Simultaneous analysis of quality of life and survival data. Statistical Methods in Medical Research 11(1): 25-48.
3. Billingham LJ, Bathers S, Burton A, Bryan S, Cullen MH. 2002. Patterns, costs and cost-effectiveness of care in a trial of chemotherapy for advanced non-small cell lung cancer. Lung Cancer 37(2): 219-225.
4. Briggs A, Clark T, Wolstenholme J, Clarke P. 2003. Missing... presumed at random: cost-analysis of incomplete data. Health Economics 12(5): 377-392.
5. Briggs A, Nixon R, Dixon S, Thompson S. 2005. Parametric modelling of cost data: some simulation evidence. Health Economics 14(4): 421-428.
6. Burton A, Billingham LJ, Bryan S. Cost-effectiveness in clinical trials: using multiple imputation to deal with incomplete cost data. Clinical Trials: Journal of the Society for Clinical Trials 4: 154-161.
7. Collett D. 1994. Modelling Survival Data in Medical Research. Chapman & Hall: London.
8. Cooper NJ, Sutton AJ, Mugford M, Abrams K R. 2003. Use of Bayesian Markov Chain Monte Carlo methods to model cost-of-illness data. Medical Decision Making 23(1): 38-53.
9. Cowles MK, Carlin BP. 1996. Markov-chain Monte-Carlo convergence diagnostics - a comparative review. Journal of the American Statistical Association 91: 883-904.
10. Cullen MH, Billingham LJ, Woodroffe CM, Chetiyawardana AD, Gower NH, Joshi R, Ferry DR, Rudd RM, Spiro SG, Cook JE, Trask C, Bessel] E, Connolly CK, Tobias J, Souhami RL. 1999. Mitomycin, ifosfamide, and cisplatin in unresectable non-small-cell lung cancer: effects on survival and quality of life. Journal of Clinical Oncology 17(10): 3188-3194.
11. Drummond MF, O'Brien B, Stoddart GL, Torrance GW. 1997. Methods for the Economic Evaluation of Health Care Programs (2nd edn). Oxford University Press: Oxford.
12. Gilks WR, Richardson S, Spiegelhalter DJ. 1996. Markov Chain Monte Carlo in Practice. Chapman & Hall: London.
13. Glick H, Polsky D, Sculman K. 2001. Trial-based economic evaluations: an overview of design and analysis. In Economic Evaluation in Health Care: Merging Theory with Practice, Drummond M, McGuire A (eds). Oxford University Press: Oxford, 113-140.
14. Greenland S, Finkle WD. 1995. A critical-look at methods for handling missing covariates in epidemiologic regression-analyses. American Journal of Epidemiology 142: 1255-1264.
15. Hahn S, Whitehead A. 2003. An illustration of the modelling of cost and efficacy data from a clinical trial. Statistics in Medicine 22(6): 1009-1024.
16. Ibrahim JG, Chen MH, Lipsitz SR. 1999. Monte Carlo EM for missing covariates in parametric regression models. Biometrics 55(2): 591-596.
17. Johnston K, Buxton MJ, Jones DR, Fitzpatrick R. 1999. Assessing the costs of healthcare technologies in clinical trials. UK: NHS R&D Health Technology Assessment Programme, vol. 3, no. 6.
18. Johnston K, Gerard K, Brown J. 1998. Generalizing costs from trials. Analyzing center selection bias in a breast screening trial, International Journal of Technology Assessment Health Care 14(3): 494-504.
19. Lin DY. 2000. Linear regression analysis of censored medical costs. Biostatistics 1(1): 35-47.
20. Lin DY. 2003. Regression analysis of incomplete medical cost data. Statistics in Medicine 22(6): 1181-1200.
21. Lipsitz SR. Ibrahim JG. 1996. A conditional model for incomplete covariates in parametric regression models. Biometrika 83: 916-922.
22. Little RJA, Rubin DB. 1989. Statistical Analysis with Missing Data. Wiley: New York.
23. Lumley T, Diehr P, Emerson S, Chen L. 2002. The importance of the normality assumption in large public health data sets. Annual Review of Public Health 23: 151-169.
24. O'Hagan A, Stevens JW, Montmartin J. 2001. Bayesian cost-effectiveness analysis from clinical trial data. Statistics in Medicine 20(5): 733-753.
25. Schafer JL. 1997. Analysis of Incomplete Multivariate Data. Chapman & Hall: London.
26. Spiegelhalter DJ. 1998. Bayesian graphical modelling: a case-study in monitoring health outcomes. Applied Statistics Journal of the Royal Statistical Society Series C 47: 115-133.
27. Spiegelhalter DJ, Best NG, Carlin BP, van der Linde A. 2002. Bayesian measures of model complexity and fit. Journal of the Royal Statistical Society (B) 64: 583-639.
28. Spiegelhalter DJ, Thomas A, Best NG, Lunn D. 2001. WinBUGS Version 1.4 User Manual. MRC Biostatistics Unit: Cambridge.
29. Stinnett AA, Mullahy J. 1998. Net health benefits: a new framework for the analysis of uncertainty in cost-effectiveness analysis. Medical Decision Making 18(2 Suppl.): S68-S80.
30. van Hout BA, Al MJ, Gordon GS, Rutten FF. 1994. Costs, effects and C/ E-ratios alongside a clinical trial. Health Economics 3(5): 309-319.